We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Eli Lilly and (LLY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of LLY and the rest of the Medical group's stocks.
Eli Lilly and is a member of the Medical sector. This group includes 756 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. LLY is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for LLY's full-year earnings has moved 6.20% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, LLY has moved about 25.15% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 10.97% on a year-to-date basis. This means that Eli Lilly and is outperforming the sector as a whole this year.
To break things down more, LLY belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual companies and currently sits at #25 in the Zacks Industry Rank. This group has gained an average of 9.36% so far this year, so LLY is performing better in this area.
Investors in the Medical sector will want to keep a close eye on LLY as it attempts to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Eli Lilly and (LLY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of LLY and the rest of the Medical group's stocks.
Eli Lilly and is a member of the Medical sector. This group includes 756 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. LLY is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for LLY's full-year earnings has moved 6.20% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, LLY has moved about 25.15% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 10.97% on a year-to-date basis. This means that Eli Lilly and is outperforming the sector as a whole this year.
To break things down more, LLY belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual companies and currently sits at #25 in the Zacks Industry Rank. This group has gained an average of 9.36% so far this year, so LLY is performing better in this area.
Investors in the Medical sector will want to keep a close eye on LLY as it attempts to continue its solid performance.